Bell Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bell Bank’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-301	Closed	-$233K	–	205
2026 Q1	$233K	Buy	301 +1	+0.3%	+$766	0.01%	174
2025 Q4	$232K	Buy	+300	New	+$204K	0.01%	177
2025 Q1	–	Sell	-300	Closed	-$214K	–	195
2024 Q4	$214K	Hold	300	–	–	0.02%	185
2024 Q3	$315K	Hold	300	–	–	0.04%	148
2024 Q2	$315K	Hold	300	–	–	0.03%	162
2024 Q1	$289K	Hold	300	–	–	0.02%	167
2023 Q4	$263K	Hold	300	–	–	0.03%	161
2023 Q3	$247K	Hold	300	–	–	0.03%	164
2023 Q2	$216K	Sell	300 -5	-2%	-$3.85K	0.02%	174
2023 Q1	$251K	Sell	305 -1	-0.3%	-$754	0.03%	168
2022 Q4	$221K	Hold	306	–	–	0.03%	174
2022 Q3	$211K	Buy	+306	New	+$193K	0.03%	171
2022 Q2	–	Sell	-300	Closed	-$210K	–	208
2022 Q1	$210K	Buy	+300	New	+$190K	0.02%	169

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bell Bank's REGN Position: Q2 2026 in Review

Bell Bank sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 301 shares — an estimated $233K sold.

Bell Bank first reported a position in REGN in Q1 2022 and held it in 13 quarters. The position peaked at $315K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Bell Bank reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bell Bank sold 301 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $233K.
Bell Bank first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 13 quarters.
Bell Bank's Regeneron Pharmaceuticals position peaked at $315K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bell Bank's 13F filing for Q2 2026, filed 16 Jul 2026.